Terms: = Thyroid cancer AND CREB1, ENSG00000118260, 1385
14 results:
1. LINC02454 promotes thyroid carcinoma progression via upregulating HMGA2 through creb1.
Cao Y; Li J; Du Y; Sun Y; Liu L; Fang H; Liang Y; Mao S
FASEB J; 2023 Dec; 37(12):e23288. PubMed ID: 37997502
[TBL] [Abstract] [Full Text] [Related]
2. MEX3A induces the development of thyroid cancer via targeting creb1.
Feng G; Wang P; Zhang H; Cheng S; Xing Y; Wang Y
Cell Biol Int; 2023 Nov; 47(11):1843-1853. PubMed ID: 37529875
[TBL] [Abstract] [Full Text] [Related]
3. Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations.
Whitmer D; Phay JE; Holt S; O'Donnell B; Nguyen J; Joseph D; Chi A; Wu S; Hao Y; Huang J; Klopper JP; Kloos RT; Kennedy GC; Shin J
Front Endocrinol (Lausanne); 2022; 13():1073592. PubMed ID: 36619548
[TBL] [Abstract] [Full Text] [Related]
4. Network-Based Genetic Profiling Reveals Cellular Pathway Differences Between Follicular thyroid Carcinoma and Follicular thyroid Adenoma.
Hossain MA; Asa TA; Rahman MM; Uddin S; Moustafa AA; Quinn JMW; Moni MA
Int J Environ Res Public Health; 2020 Feb; 17(4):. PubMed ID: 32093341
[TBL] [Abstract] [Full Text] [Related]
5. creb1/Lin28/miR-638/VASP Interactive Network Drives the Development of Breast cancer.
Hu PC; Li K; Tian YH; Pan WT; Wang Y; Xu XL; He YQ; Gao Y; Wei L; Zhang JW
Int J Biol Sci; 2019; 15(12):2733-2749. PubMed ID: 31754343
[TBL] [Abstract] [Full Text] [Related]
6. Identification and interaction analysis of key miRNAs in medullary thyroid carcinoma by bioinformatics analysis.
Zhang L; Lu D; Liu M; Zhang M; Peng Q
Mol Med Rep; 2019 Sep; 20(3):2316-2324. PubMed ID: 31322209
[TBL] [Abstract] [Full Text] [Related]
7. LINC01857 as an oncogene regulates creb1 activation by interacting with CREBBP in breast cancer.
Xiong Y; Gu Y; Wang F; Li L; Zhu M; Wang N; Mi H; Qiu X
J Cell Physiol; 2019 Aug; 234(8):14031-14039. PubMed ID: 30628071
[TBL] [Abstract] [Full Text] [Related]
8. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.
Bilen MA; Patel A; Hess KR; Munoz J; Busaidy NL; Wheler JJ; Janku F; Falchook GS; Hong DS; Meric-Bernstam F; Habra MA; Naing A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):167-71. PubMed ID: 27286994
[TBL] [Abstract] [Full Text] [Related]
9. Clinical features and analysis in 1385 Chinese patients with pituitary adenomas.
Shao S; Li X
J Neurosurg Sci; 2013 Sep; 57(3):267-75. PubMed ID: 23877272
[TBL] [Abstract] [Full Text] [Related]
10. Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on creb1 transcriptional activity.
Luise C; Merolla F; Leone V; Paladino S; Sarnataro D; Fusco A; Celetti A
PLoS One; 2012; 7(11):e49298. PubMed ID: 23145146
[TBL] [Abstract] [Full Text] [Related]
11. CCDC6 represses creb1 activity by recruiting histone deacetylase 1 and protein phosphatase 1.
Leone V; Mansueto G; Pierantoni GM; Tornincasa M; Merolla F; Cerrato A; Santoro M; Grieco M; Scaloni A; Celetti A; Fusco A
Oncogene; 2010 Jul; 29(30):4341-51. PubMed ID: 20498639
[TBL] [Abstract] [Full Text] [Related]
12. Papillary thyroid microcarcinoma: prognostic factors and treatment.
Besic N; Pilko G; Petric R; Hocevar M; Zgajnar J
J Surg Oncol; 2008 Mar; 97(3):221-5. PubMed ID: 18050283
[TBL] [Abstract] [Full Text] [Related]
13. thyroid malignancy in endemic nodular goitres: prevalence, pattern and treatment.
Lawal O; Agbakwuru A; Olayinka OS; Adelusola K
Eur J Surg Oncol; 2001 Mar; 27(2):157-61. PubMed ID: 11289751
[TBL] [Abstract] [Full Text] [Related]
14. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
[TBL] [Abstract] [Full Text] [Related]
